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The present work reports the detection of the first case of nosocomial Klebsiella oxytoca producing class A carbapenemase
KPC-2 in Brazil. The isolate KPN106 carried a 65-kb IncW-type plasmid that harbors the blaKPC gene and Tn4401b. Moreover,
we detected the presence of a class 1 integron containing a new allele, arr-8, followed by a 5=-truncated dhfrIIIc gene. In view of
the recent results, we emphasize the high variability of the bacterial and genetic hosts of this resistance determinant.
Despite the KPC enzymes being frequently associated with sev-eral members of the Enterobacteriaceae family, few reports
have described the presence of KPC in Klebsiella oxytoca isolates
(1). This work reports the first case of a KPC-2-producing K. oxy-
toca isolate in Brazil and describes its clinical data, susceptibility
profile, and molecular analysis.
A 79-year-old female patient with chronic obstructive pulmo-
nary disease and chronic renal failure was readmitted to the inten-
sive care unit (ICU) at the University Hospital Oswaldo Cruz,
Recife, Brazil, in December 2008. Due to her prior hospitalization
(41 days), the patient received upon admission imipenem (250mg
every 6 h for 2 days) and polymyxin B (500,000 U every 12 h for 8
days). Blood cultures revealed the presence of a carbapenem-re-
sistant K. oxytoca isolate (KPN106). The treatment with poly-
myxin B was maintained in combination with ciprofloxacin (400
mg every 12 h) for 7 days. The blood cultures remained positive
after antimicrobial therapy. On the 12th day of her stay, the pa-
tient died with a diagnosis of renal and respiratory failure and
sepsis. Here, we describe the microbiological and molecular anal-
ysis of this isolate.
Broth microdilution showed that the KPN106 isolate was
highly resistant to most of the antimicrobial agents tested (Table
1) according to the CLSI standard (2). The isolate was tested for
the presence of the class 1 integron, the extended-spectrum -lac-
tamase (ESBL), and class A and B carbapenemases.
Molecular analysis was carried out as described previously (3).
In addition to blaKPC-2, KPN106 presented a class 1 integron and
additional bla genes (Table 1).Moreover, it carried three plasmids
(ca. 65 kb, 15 kb, and 12 kb) that were transferable to E. coliDH5
cells by calcium chloride transformation. The sequencing of the
variable region of the class 1 integron revealed a new allele of the
ADP ribosyltransferase family that confers rifampin resistance,
arr-8 (GenBank accession number KC199968), with 75% protein
similarity with the enzymes encoded by arr-2 and arr-3 alleles.
Furthermore, we found a 5=-truncated form of the dhfrIIIc gene
that encodes dihydrofolate dehydrogenase, followed by a partial
putative insertion sequence. The Escherichia coli DH5 cells
(TF106) selected on LB agar plates containing 100g/ml ampicil-
lin acquired the 65-kb plasmid together with the blaKPC-2 gene and
class 1 integron as shown by PCR. The plasmid incompatibility
groups were determined as described previously (4), which dem-
onstrated that these plasmids belong to the IncW group in both
donor and transformant cells. This acquisition increased MICs of
E. coliDH5 cells for extended-spectrum cephalosporins, carbap-
enems, and rifampin (Table 1). Analysis of the genetic environ-
ment (5) of blaKPC revealed the presence of the transposon
Tn4401b isoform, as observed in a KPC-producingK. oxytoca iso-
late (1) and in other Enterobacteriaceaemembers (5).
Recently, there was reported the presence at the same hospital
of a 65-kb IncW-type plasmid carrying blaKPC in Tn4401c among
Enterobacteriaceae species (6). In the present study, we report a
65-kb IncW-type plasmid carrying blaKPC in Tn4401b in a K. oxy-
toca isolate, highlighting the diversity of mobile genetic elements
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TABLE 1 Phenotypic and genetic characteristics of the bacterial strains used in this work
Straina
-Lactamase/class 1 integron
cassette array
MIC (g/ml)b
AMK GEN CEF CRO CAZ FEP ATM IPM MEM ETP CIP TZP AMC RIF PMB TGC
KPN106 blaKPC-2, blaCTX-M-2, blaSHV-11,
blaTEM-1, arr-8, dhfrIIIc
16 32 256 64 64 8 128 16 16 8 8 256 128 8 0,25 1
TF106 blaKPC-2, arr-8, dhfrIIIc 16 0.25 64 64 64 8 128 16 16 8 0.25 128 32 0.25 0.25 0.03
DH5 None 0.12 0.25 8 0.06 0.5 0.5 0.5 0.12 0.015 0.003 0.004 2 1 0.03 0.12 0.06
a KPN106, K. oxytoca isolate; TF106, E. coli transformant KPN106; DH5, E. coli recipient strain.
b AMK, amikacin; GEN, gentamicin; CEF, cephalothin; CRO, ceftriaxone; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; IPM, imipenem; MEM, meropenem; ETP,
ertapenem; CIP, ciprofloxacin; TZP, piperacillin-tazobactam; AMC, amoxicillin-clavulanate; RIF, rifampin; PMB, polymyxin B; TGC, tigecycline.
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related to the blaKPC gene in this institution and the high variabil-
ity of the genetic hosts of this gene.
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